Navigation Links
GenTel licenses next generation cancer research

Madison, Wis. - Recent biochemical research into certain forms of cancer has focused on disease-related changes in the protein composition of blood. As these studies progress, significant lines of inquiry will examine not only the protein changes induced by cancer but changes in the sugar molecules that naturally attach to those proteins.

In the serum of pancreatic cancer patients,......

Full article >>> roteins (such as antibodies) in a process called glycosylation. This process occurs as part of biosynthesis and is an important determinant of protein function.

Changes in glycosylation are thought to play roles in certain disease processes.

GenTel's technology modifies the normal sugar molecules associated with antibodies printed on GenTel's arrays so that they are no longer rea......

Full article >>> ollow.

Added Nelson: "We're going to make this available to a much broader audience. We're going to expand it to look at prostate and other cancers."

The market for tumor serum analyte in-vitro diagnostic tests is approximately $1 billion per year worldwide, Negm said. Although nobody has an exact number on the glycosylation segment of that market, Negm believes that GenTel's fir......

Full article >>>
'"/> By Chris Fleissner 08/17/06

Related biology technology :

1. GenTel acquires GlaxoSmithKline chip platform
2. New angel capital centered on GenTel agreement with big pharma
3. GenTel to distribute cancer research tool
4. GenTel gets federal grant to develop allergy test
5. Madisons GenTel partners with Taiwan firm
6. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
7. GenTel BioSurfaces launches new assay platform
8. GenTel will sell Dutch firms biomolecule labeling technology
9. Bone Care, GenTel, MyWeather
10. GenTel receives $250,000 state loan
11. GenTel claims $900,000 in federal grants this year for biochip research
Post Your Comments:

(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
(Date:11/25/2015)... , November 25, 2015 ... Research Report is a professional and in-depth study ...      (Logo: ) , ... of the industry including definitions, classifications, applications and ... provided for the international markets including development trends, ...
(Date:11/24/2015)... Cepheid (NASDAQ: CPHD ) today announced ... conference, and invited investors to participate via webcast. ... December 1, 2015 at 11.00 a.m. Eastern Time ... December 1, 2015 at 11.00 a.m. Eastern Time ... York, NY      Tuesday, December 1, 2015 at ...
Breaking Biology Technology:
(Date:11/4/2015)... --> --> ... Transparency Market Research "Home Security Solutions Market - Global Industry ... 2022", the global home security solutions market is expected to reach ... market is estimated to expand at a CAGR of ... Rising security needs among customers at homes, the emergence ...
(Date:10/29/2015)...  The J. Craig Venter Institute (JCVI) policy group ... Biosecurity: Lessons Learned and Options for the Future," which ... Services guidance for synthetic biology providers has worked since ... --> --> Synthetic biology promises great ... pose unique biosecurity threats. It now is easier than ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
Breaking Biology News(10 mins):